Welcome
Support Centre
23 September 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Comprehensive studies of a new improved oral rehydration solution for diarrhoeal disease: physiological and molecular studies, clinical trials, and acceptability and efficacy studies in a rural south Indian community
ISRCTN ISRCTN72841333
DOI 10.1186/ISRCTN72841333
ClinicalTrials.gov identifier
EudraCT number
Public title Comprehensive studies of a new improved oral rehydration solution for diarrhoeal disease: physiological and molecular studies, clinical trials, and acceptability and efficacy studies in a rural south Indian community
Scientific title
Acronym N/A
Serial number at source 063150
Study hypothesis The hypothesis is that addition of amylase resistant starch to a low osmolarity Oral Rehydration Solution (ORS) will reduce the duration and severity of diarrhoea in a variety of diarrhoeal diseases including cholera and non-cholera diarrhoea. The studies consist of two randomised trials in adults and children respectively comparing the newly recommended low osmolar ORS to low osmolar ORS with added amylase resistant starch. The objective is to determine whether subjects in the trial arm will have reduced stool output and duration of diarrhoea.
Lay summary Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised, single blinded, controlled clinical trial
Countries of recruitment India
Disease/condition/study domain Diarrhoea
Participants - inclusion criteria In the adult study, all adult male patients presenting to the Emergency Service with acute severe watery diarrhoea of less than three days' duration, with moderate to severe dehydration, will be enrolled after informed written consent.

In a separate trial, male children aged six months to five years with diarrhoea (defined as more than three watery stools/24 hours) of three days or less, with mild or moderate dehydration, or those with severe dehydration who have received intravenous rehydration, will be enrolled after informed written consent from the parent.
Participants - exclusion criteria In the adult trial, subjects without clinical dehydration, those with presence of blood in stool, and presence of significant systemic illness unrelated to the diarrhoea, will be excluded.

In the children's trial, bloody diarrhoea, concurrent severe illness (such as pneumonia, meningitis or infections requiring antibiotics), and severe malnutrition Grade III and IV will be treated as exclusion criteria.
Anticipated start date 01/01/2005
Anticipated end date 31/01/2007
Status of trial Completed
Patient information material
Target number of participants To be added - recruitment ends in 31st December 2006
Interventions Eligible subjects will be randomised to one of two treatment arms to receive either reduced osmolarity ORS or reduced osmolarity ORS along with amylase resistant starch. All other treatment measures will be identical in the two groups. ORS will be administered according to World Health Organisation (WHO) treatment guidelines for management of acute diarrhoea. Stool consistency and weight will be determined by personnel unaware of the treatment received by the patient.

The adult trial is closed to recruitment and follow up is complete. Therefore a new anticipated end date of 31st January 2007 has been provided. The previous end date of this trial was 15/03/2006.

The trial in children is continuing to recruit patients.
Primary outcome measure(s) 1. Stool weight in successive 12 hour periods
2. Stool weight in the second 24 hours
3. Time to last unformed stool
4. Requirement for unscheduled intravenous fluids
Secondary outcome measure(s) No secondary outcome measures
Sources of funding The Wellcome Trust (UK) (grant ref: 063150)
Trial website
Publications Results in http://www.ncbi.nlm.nih.gov/pubmed/18270575
Contact name Mr  Balakrishnan S  Ramakrishnan
  Address Christian Medical College
Williams Research Building
Department of Gastrointestinal Science
Ida Scudder Road
  City/town Vellore
  Zip/Postcode 632004
  Country India
  Tel +91 (0)416 2282052
  Fax +91 (0)416 2232035
  Email rama@cmcvellore.ac.in
Sponsor Christian Medical College (India)
  Address c/o George M Chandy
Ida Scudder Road
  City/town Vellore
  Zip/Postcode 632004
  Country India
  Tel +91 (0)416 2282052
  Fax +91 (0)416 2232035
  Email directorate@cmcvellore.ac.in
  Sponsor website: http://cmcvellore.ac.in
Date applied 22/07/2005
Last edited 22/03/2013
Date ISRCTN assigned 22/07/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.